Top

Archives of Gynecology and Obstetrics

Published in:

01-09-2012 | Gynecologic Oncology

Oestrogen receptor α mediates 17β-estradiol enhancement of ovarian cancer cell motility through up-regulation of survivin expression

Authors: Jing Zhu, Xin Lu, Ke-Qin Hua, Hong Sun, Yin-Hua Yu, You-Ji Feng

Published in: Archives of Gynecology and Obstetrics | Issue 3/2012

Abstract

Objective

To determine the role of oestrogen receptor α (ERα) in the regulation of survivin expression by 17β-estradiol (E₂) in ovarian cancer cells and to evaluate the mechanism of E₂ action on ovarian cancer cell migration.

Methods

We performed RT-PCR and Western blot analysis to assess the expression of ERα in the ovarian cancer cell lines NIH:OVCAR-3 and SKOV-3. Full-length ERα cDNA was reintroduced into SKOV-3 cells through stable transfection. After treatment with E₂, with or without pre-incubation of anti-oestrogen compound ICI 182780, RT-PCR and Western blot analysis were performed to detect survivin expression at the mRNA and protein levels. RNA interference (RNAi) was used to inhibit the expression of survivin in SKOV-3 cells. Wound healing-induced migration and Matrigel invasion experiments were performed to determine the motility of ovarian cancer cells. RT-PCR and gelatin zymography were used to detect the expression and activity of MMP-9 in SKOV-3 cells.

Results

A stably transfected clone with over-expression of ERα, SKOV-α, was isolated. Exogenous or endogenous expression of ERα in SKOV-3 or NIH:OVCAR-3 cells resulted in a significant up-regulation of survivin in the presence of E₂. Pre-treatment with ICI 182780 attenuated the up-regulation of survivin by E₂. Previous data from our laboratory showed that E₂ enhanced the motility of ovarian cancer cells. RNAi strongly inhibited survivin expression in SKOV-3 cells. Knock-down of survivin expression reduced the migration and invasion of SKOV-3 cells, which correlated with down-regulation of MMP9 mRNA expression and activity.

Conclusions

ERα may be responsible for the up-regulation of survivin after E₂ treatment in ovarian cancer cells. The mechanism of oestrogen-promoted ovarian cancer metastasis may due to the up-regulation of survivin conducted through the ERα signalling pathway.

Greenlee RT, Murray T, Bolden S, Wingo PA (2000) Cancer statistics 2000. CA Cancer J Clin 50:7–33PubMedCrossRef

Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics 2007. CA Cancer J Clin 57:43–66PubMedCrossRef

Scully RE (1995) Pathology of ovarian cancer precursors. J Cell Biochem Suppl 23:208–218PubMedCrossRef

Perniconi SE, Simões MJ, Simões RS, Haidar MA, Baracat EC, Soares Junior JM (2008) Proliferation of the superficial epithelium of ovaries in senile female rats following oral administration of conjugated equine estrogens. Clinics 63:381–388PubMedCrossRef

Syed V, Ulinski G, Mok SC, Yiu GK, Ho SM (2001) Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res 61:6768–6776PubMed

Havrilesky LJ, McMahon CP, Lobenhofer EK, Whitaker R, Marks JR, Berchuck A (2001) Relationship between expression of coactivators and corepressors of hormone receptors and resistance of ovarian cancers to growth regulation by steroid hormones. J Soc Gynecol Investig 8:104–113PubMedCrossRef

Pujol P, Rey JM, Nirde P, Roger P, Gastaldi M, Laffargue F et al (1998) Differential expression of estrogen receptor-alpha and -beta messenger RNAs as a potential marker of ovarian carcinogenesis. Cancer Res 58:5367–5373PubMed

Twal WO, Czirok A, Hegedus B, Knaak C, Chintalapudi MR, Okagawa H et al (2001) Fibulin-1 suppression of fibronectin-regulated cell adhesion and motility. J Cell Sci 114:4587–4598PubMed

Rochefort H, Chalbos D, Cunat S, Lucas A, Platet N, Garcia M (2001) Estrogen regulated proteases and antiproteases in ovarian and breast cancer cells. J Steroid Biochem Mol Biol 76:119–124PubMedCrossRef

10.

Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ (2001) Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 285:1460–1465PubMedCrossRef

11.

Anderson GL, Judd HL, Kaunitz AM, Barad DH, Beresford SAA, Pettinger M et al (2003) Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women’s Health Initiative Randomized Trial. JAMA 290:1739–1748PubMedCrossRef

12.

Li F, Altieri DC (1999) The cancer antiapoptosis mouse survivin gene: characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression. Cancer Res 59:3143–3151PubMed

13.

Sah NK, Khan Z, Khan GJ, Bisen PS (2006) Structural, functional and therapeutic biology of survivin. Cancer Lett 244:164–171PubMedCrossRef

14.

Suzuki A, Ito T, Kawano H, Hayashida M, Hayasaki Y, Tsutomi Y et al (1910) Survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell death. Oncogene 1346–1353:2000

15.

Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S et al (2002) Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 2117:2613–2622CrossRef

16.

Azuhata T, Scott D, Griffith TS, Miller M, Sandler AD (2006) Survivin inhibits apoptosis induced by TRAIL, and the ratio between survivin and TRAIL receptors is predictive of recurrent disease in neuroblastoma. J Pediat Surg 418:1431–1440CrossRef

17.

Grossman D, Kim PJ, Blanc-Brude OP, Brash DE, Tognin S, Marchisio PC et al (1087) Transgenic expression of surviving in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53. J Clin Invest 991–999:2001

18.

Yamamoto T, Manome Y, Nakamura M, Tanigawa N (2002) Downregulation of survivin expression by induction of the effector cell protease receptor-1 reduces tumor growth potential and results in an increased sensitivity to anticancer agents in human colon cancer. Eur J Cancer 3817:2316–2324CrossRef

19.

Ryan BM, O’Donovan N, Duffy MJ (2009) Survivin: a new target for anti-cancer therapy. Cancer Treat Rev 35:553–562PubMedCrossRef

20.

Hua KQ, Feng WW, Cao Q, Zhou XR, Lu X, Feng YJ (2008) Estrogen and progestin regulate metastasis through the PI3K/AKT pathway in human ovarian cancer. Int J Oncol 33:959–967PubMed

21.

Ai ZH, Yin LH, Zhou XR, Zhu Y, Zhu DM, Yu YH, Feng YJ (2006) Inhibition of survivin reduces cell proliferation and induces apoptosis in human endometrial cancer. Cancer 107:746–756PubMedCrossRef

22.

Liguang Z, Peishu L, Hongluan M, Hong J, Rong W, Wachtel MS et al (2007) Survivin expression in ovarian cancer. Exp Oncol 29:121–125PubMed

23.

Ferrandina G, Legge F, Martinelli E, Ranelletti FO, Zannoni GF, Lauriola L et al (2005) Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters. Br J Cancer 92:271–277PubMed

24.

Kleinberg L, Florenes VA, Silins I, Haug K, Trope CG, Nesland JM et al (2007) Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma. Cancer 109:228–238PubMedCrossRef

25.

Qian X, Xi X, Li L (2011) Nuclear survivin is associated with malignant potential in epithelial ovarian carcinoma. Appl Immunohistochem Mol Morphol 19:126–132PubMedCrossRef

26.

Johnson ME, Howerth EW (2004) Survivin: a bifunctional inhibitor of apoptosis protein. Vet Pathol 41:599–607PubMedCrossRef

27.

Athanassiadou P, Grapsa D, Athanassiades P, Gonidi M, Athanassiadou AM, Tsipis A et al (2008) The prognostic significance of COX-2 and survivin expression in ovarian cancer. Pathol Res Pract 204:241–249PubMedCrossRef

28.

Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S et al (2002) Human survivin is negatively regulated by wild type p53 and participate in p53-dependent apoptotic pathway. Oncogene 2:2613–2622CrossRef

29.

Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M (2002) Transcriptional repression of the anti-apoptotic survivin gene wild type p53. J Biol Chem 277:3247–3257PubMedCrossRef

30.

Robertson JFR (2001) ICI 182,780 (Fulvestrant^™)—the first oestrogen receptor down -regulator—current clinical data. Brit J Cancer 85(Suppl 2):11–14PubMed

31.

Frasor J, Danes JM, Komm B, Chang KCN, Lyttle CR, Katzenellenbogen BS (2003) Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144:4562–4574PubMedCrossRef

32.

Moggs JG, Murphy TC, Lim FL, Moore DJ, Stuckey R, Antrobus K et al (2005) Anti-proliferative effect of estrogen in breast cancer cells that re-express ERα is mediated by aberrant regulation of cell cycle genes. J Mol Endocrinol 34:535–551PubMedCrossRef

33.

Yu L, Wang CY, Shi JD, Miao L, Du XL, Mayer D et al (2011) Estrogens promote invasion of prostate cancer cells in a paracrine manner through up-regulation of matrix metalloproteinase 2 in prostatic stromal cells. Endocrinology 152:773–781PubMedCrossRef

34.

Sanchez AM, Flamini MI, Baldacci C, Goglia L, Genazzani AR, Simoncini T (2010) Estrogen receptor-α promotes breast cancer cell motility and invasion via focal adhesion kinase and N-WASP. Mol Endocrinol 24:2114–2125PubMedCrossRef

35.

Pennati M, Folini M, Zaffaroni N (2007) Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis 28:1133–1139PubMedCrossRef

36.

McManus M, Sharp P (2002) Gene silencing in mammals by small interfering RNAs. Genetics 3:737–747PubMed

37.

Hojilla CV, Mohammed FF, Khokha R (2003) Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. Br J Cancer 89:1817–1821PubMedCrossRef

Title: Oestrogen receptor α mediates 17β-estradiol enhancement of ovarian cancer cell motility through up-regulation of survivin expression
Authors: Jing Zhu
Xin Lu
Ke-Qin Hua
Hong Sun
Yin-Hua Yu
You-Ji Feng
Publication date: 01-09-2012
Publisher: Springer-Verlag
Published in: Archives of Gynecology and Obstetrics / Issue 3/2012
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-012-2368-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Oestrogen receptor α mediates 17β-estradiol enhancement of ovarian cancer cell motility through up-regulation of survivin expression

Abstract

Objective

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2012

Endometrioma in abdominal scars: case reports of four cases and review of the literature

The underestimation of immaturity in late preterm infants

Informed consent in clinical practice and literature overview

The Bishop Score as a determinant of labour induction success: a systematic review and meta-analysis

Effect of epidural block on 24-hour urine protein in pregnant rat models with preeclampsia

Acute lobar nephronia in pregnancy: a rarely reported entity in obstetric renal medicine